OpinionViewpoints

Early Outpatient Treatment for COVID-19: The Evidence

Save
Early Outpatient Treatment for COVID-19: The Evidence
fusebulb/Shutterstock
Paul E. Alexander
Updated:
Commentary

The evidence accumulated very early on in the pandemic that the use of sequenced multi-drug therapeutics (SMDT) under physician guidance was beneficial and that some medications were safe and effective. We refer to repurposed therapeutics that have been regulatory approved and have been used in some instances for decades for other illnesses.

Paul E. Alexander
Paul E. Alexander
Author
Dr. Paul Elias Alexander is a COVID-19 consultant researcher in the US-C19 research group. He was formerly an assistant professor at McMaster University in evidence-based medicine and research methods; a COVID pandemic evidence-synthesis consultant-adviser to WHO-PAHO Washington; and senior adviser on COVID pandemic policy at Health and Human Services. He was appointed in 2008 at WHO as a regional specialist/epidemiologist in Europe's regional office in Denmark, worked for the government of Canada as an epidemiologist for 12 years, was appointed as the Canadian in-field epidemiologist (2002–2004), and worked from 2017 to 2019 at Infectious Diseases Society of America as the evidence synthesis meta-analysis systematic review guideline development trainer. Dr. Alexander holds masters level study from York University Canada, and a masters in epidemiology from the University of Toronto, a masters in evidence-based medicine from the University of Oxford, and a doctorate in evidence-based medicine and research methods from McMaster University in Canada.
Related Topics